Growth Metrics

Merck (MRK) Total Non-Current Liabilities (2016 - 2026)

Merck has reported Total Non-Current Liabilities over the past 17 years, most recently at $75.1 billion for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 25.05% to $75.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $75.1 billion through Mar 2026, up 25.05% year-over-year, with the annual reading at $76.6 billion for FY2025, N/A changed from the prior year.
  • Total Non-Current Liabilities was $75.1 billion for Q1 2026 at Merck, down from $76.6 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $76.6 billion in Q4 2025 and troughed at $600.0 million in Q1 2022.
  • The 5-year median for Total Non-Current Liabilities is $675.0 million (2022), against an average of $24.9 billion.
  • Year-over-year, Total Non-Current Liabilities changed 0.0% in 2023 and then skyrocketed 7908.93% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $600.0 million in 2022, then increased by 25.0% to $750.0 million in 2023, then changed by 0.0% to $750.0 million in 2024, then soared by 10109.6% to $76.6 billion in 2025, then fell by 1.91% to $75.1 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Total Non-Current Liabilities are $75.1 billion (Q1 2026), $76.6 billion (Q4 2025), and $70.0 billion (Q3 2025).